246 related articles for article (PubMed ID: 30094103)
1. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.
Sun LL; Yang RY; Li CW; Chen MK; Shao B; Hsu JM; Chan LC; Yang Y; Hsu JL; Lai YJ; Hung MC
Am J Cancer Res; 2018; 8(7):1307-1316. PubMed ID: 30094103
[TBL] [Abstract][Full Text] [Related]
2. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
3. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
[TBL] [Abstract][Full Text] [Related]
4. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract][Full Text] [Related]
5. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
Ngoi NYL; Peng G; Yap TA
Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
Song N; Bai M; Che X; Li Z; Jing W; Li C; Teng Z; Qu X; Liu Y
Med Oncol; 2020 Apr; 37(5):47. PubMed ID: 32277292
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
9. From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation.
Mouw KW; Konstantinopoulos PA
Br J Cancer; 2018 Apr; 118(7):933-935. PubMed ID: 29531322
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.
Shevtsov M; Sato H; Multhoff G; Shibata A
Front Oncol; 2019; 9():156. PubMed ID: 30941308
[TBL] [Abstract][Full Text] [Related]
12. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
13. DNA Repair and Signaling in Immune-Related Cancer Therapy.
Kakoti S; Sato H; Laskar S; Yasuhara T; Shibata A
Front Mol Biosci; 2020; 7():205. PubMed ID: 33102516
[TBL] [Abstract][Full Text] [Related]
14. Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1.
MacDonald WJ; Verschleiser B; Carlsen L; Huntington KE; Zhou L; El-Deiry WS
Am J Cancer Res; 2023; 13(7):2938-2947. PubMed ID: 37559982
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation.
Xia W; Zhu J; Tang Y; Wang X; Wei X; Zheng X; Hou M; Li S
Front Oncol; 2020; 10():821. PubMed ID: 32537433
[TBL] [Abstract][Full Text] [Related]
18. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
Hays E; Bonavida B
Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
[TBL] [Abstract][Full Text] [Related]
19. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
[No Abstract] [Full Text] [Related]
20. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
